7.P. Round table: Bridging the gap between knowledge and practice in public health genomics

Organised by: EUPHA section on Public health genomics
Contact: adany.roza@sph.unideb.hu

Chairperson(s): Roza Adany - Hungary, Stefania Boccia - Italy

The “genomic revolution” is already transforming science, especially medicine. Genomic medicine have captured the interest and enthusiasm of not only the researchers, but also the public and resulted in the creation of both realistic and unrealistic expectations. Among these expectations using genomic information for the benefit of population health is the most obvious. “The public health community, with its commitment to equity, must take the opportunity to engage with genomic knowledge, ensuring that it advances the population’s health.” as it is stated by the expert group releasing the Rome Declaration “Beyond public health
The evaluation of genetic tests: a Health Technology Assessment exercise?
Paolo Villari

C Marzuillo1, E Pitini1, E D’Andrea1, E Di Maria1, P Villari1
1Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy
2Department of Health Sciences, University of Genova, Genova, Italy
Contact: paolo.villari@uniroma1.it

Genetic tests are offering new opportunities to clinical decision making and personalized medicine. Despite different evaluation models have been developed to guide their implementation, none of them reached a generalized consensus. Our aim was to realize a new model, based on the best evidences and practices available that could become a reference methodology for Italy and other countries.

We conduct a systematic review of existing models, guidelines and reviews dealing with genetic tests evaluation and a Delphi consensus procedure involving Italian experts of public health genomics. The evaluation dimensions retrieved through the systematic review and the Delphi procedure were combined, defined and organized in the final model, based on the analysis of the literature and the experience of the working group itself. The final draft of the model was revised by the experts and suggested changes were made.

Our model combines the specific evaluation dimensions for genetic tests of the ACCE model with the HTA process. The first two sections of the model guide the collection of evidences for the genetic test and its delivery models through eight evaluation dimensions (Genetic test: analytic validity; clinical validity; clinical utility; personal utility. Delivery models: organizational aspects; economic evaluation; ethical, legal and social implications; patient’s point of view). The third section highlights the research priorities. The fourth shows the criteria to recommend on the use of the genetic test (net benefit, cost-effectiveness, feasibility).

The most innovative aspect of the proposed model is its focus on the delivery models, including the levels of care, the health care programs and the clinical pathways in which the test is delivered. It will be useful to evaluate both the new genetic tests to be introduced in the public health practice and those already in use, guiding the decisions of a large audience of stakeholders.

Barriers and facilitating factors for implementation of genetic services
Martina Cornel

MC Cornel
Clinical Genetics/EMGO Institute for Health and Care Research, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
Contact: MC.Cornel@vumc.nl

Genetics and genomics have developed fast in the last decade, but have not revolutionized medicine, as some had expected. Translation of research findings to public health applications is lagging behind.

Many people in the EU suffer from rare conditions or more frequent monogenic subtypes of common disorders, for which genetic tests could contribute to personalized medicine. However, to move knowledge from bench to population requires planned implementation activities.

Beyond translation from mouse to man, education of public and professionals is needed. Transdisciplinary guidelines will attune perspectives of laboratory geneticists, expert clinicians and primary care. Monitoring of key performance indicators may help to evaluate to what extent implementation has been successful. Health technology assessment is needed to discern genetic tests with proven clinical utility from the offer of all kind of tests without clinical utility. Associations between genetic variants and disease risks of clinical relevance have been established, for instance for hereditary breast and ovarian cancer, colon cancer (FAP, HNPCC), cardiovascular disorders (familial hypercholesterolaemia, hypertrophic cardiomyopathy). Neonatal screening is adequately monitored in several EU countries. These examples can be used to reflect on the possibilities of using the new genetics in public health. For the first group of diseases cascade screening (inviting family members) is a very effective approach.

Stakeholders must actively plan the translation of clinically useful knowledge to the population. Transdisciplinary collaboration is needed to attune priorities and key values. Monitoring of the most important indicators will support change management.

Genetic testing between private and public interests: ethical and legal implications
Judit Sándor

J Sándor
Center for Ethics and Law in Biomedicine, Central European University, Budapest, Hungary
Contact: sandorj@ceu.edu

In Europe there is a wide variety of genetic tests that various private companies offer to patients or consumers. As a result, more and more people have become curious about their genetic predisposition and susceptibility. However, most public health care systems are not adequately prepared for responding to the results of genetic tests. For example, there is no available therapy for the identified genetic condition. This discrepancy between the newly emerging expectations and the insufficient response can contribute to a
further rift between the public and private sectors of health care. Individual genetic test results may also trigger the need for personalized medicine and may open up a competition between the two fields in offering further genetic tests and medical exams. In this context, how should the public health system deal with the challenges of the private testing? Will private genetic testing transform health care from a solidarity-based health care to a risk specific health care?